Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Supercharge Your Remote Work Arrangement with These Game-Changing Instruments - 26 Well known Nissan Vehicles in the U.S.
- 3Eating ultra-processed foods could raise precancerous polyp risk for women under 50, according to research
- 4Select Your Cherished Fish
- 5Manual for Mountain Objections on the planet
- Luigi Mangione‘s lawyers say Bondi’s death penalty decision was tainted by conflict of interest
- Roche breast cancer pill cuts risk of disease recurrence by 30% in trial
- Executed Iranian nuclear scientist confessed to aiding Israel after torture, threats against mother
- Collierville residents with no power as temperatures plunge
- King Charles III says he is reducing cancer treatment schedule in 2026
- All the ways Marjorie Taylor Greene has shifted her approach lately — and why Trump is 'surprised at her'
- Pick Your Top Method for starting the Morning
- Step by step instructions to Explore the Close to home Consequence of Cellular breakdown in the lungs
- Web designers for Independent ventures
